COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Valneva SE (ISIN: FR0004056851) with BUY rating & reduced target price to EUR 6.30. FDA suspends Valneva's chikungunya vaccine; VLA15 Lyme disease vaccine prospects remain positive -
-
-
COMMUNIQUÉ DE PRESSE
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Valneva SE announces FDA's suspension of IXCHIQ® chikungunya vaccine license in the U.S. due to serious adverse events, despite reported cases consistent with clinical trials. Sales impact to be evaluated -
-
-
